## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-10.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($764.55)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230808 | Bullish | Relevance: 100%
- McKesson Corporation (MCK) experienced a stock price drop of nearly 3% on December 3, 2025, closing at $805.37, despite being a strong performer in U.S. healthcare throughout the year. The pullback is attributed to profit-taking, institutional portfolio adjustments, and investors processing new guidance and oncology initiatives. The company is actively reshaping its portfolio by spinning off its Medical-Surgical Solutions segment and focusing on oncology, specialty drugs, and tech-enabled services, with analysts generally bullish on its long-term prospects.

**2. McKesson Corporation pushes for biopharma collaboration in cancer care**
- Source: Traders Union | 20251203T025213 | Bullish | Relevance: 100%
- McKesson Corporation advocates for increased collaboration within the biopharma industry to enhance cancer care. The company emphasizes the necessity for biopharma companies to partner with community oncologists to support policies that protect access and foster innovation in the medical field amidst rapid policy changes.

**3. McKesson’s Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care**
- Source: Business Wire | 20251201T160626 | Bullish | Relevance: 100%
- McKesson Corporation announced the publication of its first Advancing Community Oncology Report, detailing trends and opportunities in community-based oncology. The report highlights strategies for biopharma and community practices to accelerate precision medicine, expand clinical trial access, and prepare for technology-driven care, based on insights from over 200 surveyed oncologists and staff, and industry experts. Key findings emphasize the need for collaboration to address challenges like keeping pace with innovations and accessing clinical trials, ultimately aiming to improve patient outcomes in community settings.

**4. McKesson’s Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care**
- Source: 01net | 20251201T160617 | Bullish | Relevance: 100%
- McKesson Corporation has released its first-ever Advancing Community Oncology Report, highlighting trends and opportunities in community-based oncology. The report, based on surveys and conference insights, identifies key areas for biopharma and community practices to collaborate, including accelerating precision medicine, expanding clinical trial access, and preparing for technology-driven care. The goal is to strengthen the community oncology ecosystem and improve patient access to innovative therapies.

**5. Brandes Investment Partners LP Sells 151,828 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251203T050841 | Somewhat-Bullish | Relevance: 100%
- Brandes Investment Partners LP significantly reduced its stake in McKesson Corporation, selling 151,828 shares and retaining 177,220 shares valued at approximately $129.9 million. This comes after McKesson reported strong Q3 earnings, beating EPS expectations but slightly missing revenue estimates, and announced a quarterly dividend of $0.82. Several other institutional investors also adjusted their positions in MCK, while analysts have maintained a "Moderate Buy" rating with an average price target of $887.69.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |
| 2025-11-06 | UBS | $980 | $920 | +7% |
| 2025-11-06 | Baird | $927 | $873 | +6% |
| 2025-11-06 | Morgan Stanley | $916 | $857 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Wells Fargo | main | Equal-Weight |
| 2025-11-06 | UBS | main | Buy |
| 2025-11-06 | Baird | main | Outperform |
| 2025-11-06 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-10.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (4 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.0B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 18.4 |
| Current P/E | 20.8 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.1% to -7.5% (-10.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.5pp (needs >4.0% for momentum thesis). AM_20 at -5.7% indicates price below own 20MA trend. Underperforming sector by 7.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-8.00), momentum weakening. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: -FTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.51% (CS: 4) | Weak |
| RSI_14 | 39.2 | Neutral |
| MACD Histogram | -8.00 | Bearish |
| vs SMA20 | 0.942x | Below |
| vs SMA50 | 0.994x | Below |
| vs SMA200 | 1.117x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $805.37
- **Stop Loss:** $764.55 (5.1% risk)
- **Target:** $887.01 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 23
- **Position Value:** $18,523.51
- **Portfolio %:** 18.52%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*